Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

B-cell Surface Reactive Antibodies for the Treatment of B-Cell Chronic Lymphocytic Leukemia

Posted Oct 11 2009 5:00pm

Description of Invention:
B-cell chronic lymphocytic leukemia (B-CLL) is a cancer characterized by a progressive accumulation of functionally incompetent lymphocytes. Despite high morbidity and mortality, the only available potential cure is allogeneic hematopoietic stem cell transplantation (alloHSCST). However, there is less than a 50% chance of finding a matching bone marrow or blood donor for B-CLL patients. Other clinically tested targeted therapies such as rituximab and alemtuzumab target both malignant and normal B cells, resulting in immunosuppression.

Available for licensing are fully human monoclonal antibodies that were selected from the first human post-alloHSCT antibody library. The library was generated from a time point after transplantation at which antibodies to B-CLL cell surface antigens peaked, thus indicating its therapeutic value. Utilizing phage display, the investigators generated a panel of fully human monoclonal antibodies that strongly bind to the same epitope on a B-CLL cell surface antigen. Weaker binding to normal B cells, but not to other lymphocytes, was observed. These fully human monoclonal antibodies provide readily available treatment that selectively targets malignant B cells.

Applications:
  • B-cell chronic lymphocytic leukemia therapeutics
  • Method to inhibit the growth of malignant B-cells
  • Method to detect B-cell tumors


Advantages:
  • Selective targeting of malignant B-cell surface antigens that are minimally non-damaging to non-diseased cells
  • Readily available therapeutics without the need for bone marrow or blood transplantation


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Christoph Rader (NCI)


Patent Status:
HHS, Reference No. E-163-2009/0
PCT, Application No. PCT/US10/34491 filed 12 May 2010


Relevant Publication:
  1. S Baskar, JM Suschak, I Samija, R Srinivasan, RW Childs, SZ Pavletic, MR Bishop, C Rader. A human monoclonal antibody drug and target discovery platform for B-cell chronic lymphocytic leukemia based on allogeneic hematopoietic stem cell transplantation and phage display. Blood, in press. Epub ahead of print, 2009 Aug 10. [ PubMed abs ]


Licensing Status:
Available for licensing.

Collaborative Research Opportunity:
The Center for Cancer Research, Experimental Transplantation and Immunology Branch, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize fully human monoclonal antibodies selected from post-alloHSCT antibody libraries. Please contact John D. Hewes, Ph.D. at 301-435-3121 or hewesj@mail.nih.gov for more information.


Portfolios:
Cancer
Cancer - Diagnostics
Cancer - Therapeutics



For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220


Ref No: 2025

Updated: 10/2009

Post a comment
Write a comment:

Related Searches